Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
用于1型和2型糖尿病的辅助治疗。
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.